Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spyre Therapeutics ( (SYRE) ) has shared an update.
On April 14, 2026, Spyre Therapeutics, Inc. entered into an underwriting agreement with a syndicate of banks to offer 6,500,000 shares of common stock at $62.00 per share, along with a 30-day option for underwriters to purchase up to an additional 975,000 shares. The underwriters exercised this option in full on April 15, 2026, and the offering closed on April 16, 2026, generating approximately $463.5 million in gross proceeds before expenses.
Spyre plans to use the net proceeds to advance its inflammatory bowel disease and rheumatic disease programs, funding preclinical studies, clinical trials, manufacturing, and Phase 3 readiness activities for its antibody portfolio, as well as for working capital and general corporate purposes. The capital raise, conducted under an effective shelf registration with the U.S. Securities and Exchange Commission, strengthens the company’s balance sheet and supports its progression toward late-stage development in competitive autoimmune markets.
The most recent analyst rating on (SYRE) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.
Spark’s Take on SYRE Stock
According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.
The score is driven primarily by solid balance-sheet strength (no debt, higher equity) and strong technical momentum. Offsetting these positives are weak current fundamentals (minimal revenue, large losses and cash burn) and limited valuation support due to a negative P/E and no dividend.
To see Spark’s full report on SYRE stock, click here.
More about Spyre Therapeutics
Spyre Therapeutics, Inc. is a biopharmaceutical company focused on developing antibody-based therapies for inflammatory bowel disease and rheumatic diseases. Its programs target autoimmune and inflammatory conditions, with a pipeline that includes preclinical and clinical-stage assets aimed at addressing significant unmet medical needs in these chronic disorders.
Average Trading Volume: 895,825
Technical Sentiment Signal: Buy
Current Market Cap: $5.42B
See more data about SYRE stock on TipRanks’ Stock Analysis page.